| scholarly article | Q13442814 |
| P50 | author | Elaine Peskind | Q92094304 |
| Hilkka Soininen | Q38636823 | ||
| Taher Darreh-Shori | Q48268518 | ||
| Agneta Nordberg | Q63126486 | ||
| P2093 | author name string | Gina Eagle | |
| Roger Lane | |||
| Malahat Mousavi | |||
| P2860 | cites work | A new and rapid colorimetric determination of acetylcholinesterase activity | Q26778487 |
| Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine | Q27638306 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Promoter elements and alternative splicing in the human ACHE gene | Q28256886 | ||
| Virtues and woes of AChE alternative splicing in stress-related neuropathologies | Q28300311 | ||
| Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease | Q32065439 | ||
| Safety of lumbar puncture procedures in patients with Alzheimer's disease. | Q33671485 | ||
| Structural roles of acetylcholinesterase variants in biology and pathology | Q33734605 | ||
| Mind over immunity. | Q34293999 | ||
| Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology | Q34481807 | ||
| Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period | Q34559914 | ||
| The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design | Q34564655 | ||
| Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease | Q34571834 | ||
| Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action | Q34760327 | ||
| Acetylcholinesterase and its inhibition in Alzheimer disease | Q35800622 | ||
| Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology | Q36134380 | ||
| Acetylcholinesterase-amyloid-beta-peptide interaction: effect of Congo Red and the role of the Wnt pathway | Q36172624 | ||
| Targeting acetylcholinesterase and butyrylcholinesterase in dementia | Q36219900 | ||
| Coexpression of cholinergic and noradrenergic phenotypes in human and nonhuman autonomic nervous system | Q36996150 | ||
| Excess "read-through" acetylcholinesterase attenuates but the "synaptic" variant intensifies neurodeterioration correlates | Q37237186 | ||
| Intercellular communication that mediates formation of the neuromuscular junction | Q40891776 | ||
| Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease | Q42646408 | ||
| Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. | Q43758864 | ||
| Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain | Q43889102 | ||
| Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months | Q44115102 | ||
| Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients | Q44301966 | ||
| Acetylcholinesterase induces the expression of the beta-amyloid precursor protein in glia and activates glial cells in culture. | Q44695558 | ||
| Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. | Q44792320 | ||
| Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline | Q45079116 | ||
| Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. | Q46456098 | ||
| Hydrolytic and nonenzymatic functions of acetylcholinesterase comodulate hemopoietic stress responses | Q46859560 | ||
| Pathological correlates of dementia in Alzheimer's disease | Q48134613 | ||
| Anticholinesterases induce multigenic transcriptional feedback response suppressing cholinergic neurotransmission | Q48152719 | ||
| PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. | Q48231733 | ||
| Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine | Q48323376 | ||
| Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter | Q48366245 | ||
| Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. | Q48376795 | ||
| Astroglia up-regulate transcription and secretion of 'readthrough' acetylcholinesterase following oxidative stress | Q48449247 | ||
| Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease | Q48486634 | ||
| Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation | Q48487747 | ||
| Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. | Q48488443 | ||
| Different glycosylation in acetylcholinesterases from mammalian brain and erythrocytes | Q48498492 | ||
| Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. | Q48839189 | ||
| Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain | Q49055563 | ||
| The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia | Q49247135 | ||
| Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. | Q50726972 | ||
| Cholinergic status modulations in human volunteers under acute inflammation. | Q51973293 | ||
| On the multifunctionality of cholinesterases. | Q52036055 | ||
| Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. | Q53208961 | ||
| The C-terminal T peptide of cholinesterases: structure, interactions, and influence on protein folding and secretion | Q79456448 | ||
| Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease | Q79841525 | ||
| P433 | issue | 1 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 4-14 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Current Alzheimer Research | Q5195031 |
| P1476 | title | Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients | |
| P478 | volume | 6 |
| Q35428213 | A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease |
| Q37070395 | A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease |
| Q38024391 | Acetylcholinesterase inhibitors: a patent review (2008 - present). |
| Q64255298 | Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease |
| Q38289739 | Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases |
| Q53313228 | Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. |
| Q36273566 | Conjugates of γ-Carbolines and Phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer Disease |
| Q37807637 | Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease |
| Q36632702 | Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application |
| Q50612791 | Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease. |
| Q43188727 | Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study |
| Q51491144 | Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease. |
| Q37601479 | Emerging cognitive enhancing drugs |
| Q50597460 | Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease. |
| Q38208461 | Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease |
| Q38899961 | Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management. |
| Q37158584 | Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load |
| Q38350602 | Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia |
| Q33596451 | Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia |
| Q58794595 | Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease: An Overview of Switching Between Pharmacological Agents |
| Q38247181 | Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions |
| Q50783671 | Two galantamine titration regimens in patients switched from donepezil. |
| Q24235324 | Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementia |
Search more.